New insights about COVID-19 treatments for cancer patients
July 24, 2020
The new COVID-19 and Cancer Consortium study shows that patients who were treated with the antiviral drug remdesivir fared the best.
OncLive: Dr. Mesa on rechallenging with JAK inhibitor therapy in MPNs
July 23, 2020
In this video, Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms (MPNs). Watch the interview.
OncLive: Dr. Mesa on recent data with momelotinib in MPNs and myelofibrosis
July 20, 2020
Ruben Mesa, MD, director of the Mays Cancer Center, discusses recent data with momelotinib in myelofibrosis. Read and watch the story.
Study hints at novel therapeutic target for Ewing sarcoma
July 16, 2020
New insights into Ewing sarcoma, an aggressive childhood cancer, were published July 15 in the prestigious journal Nature.
Finding published in Nature hints at novel therapeutic target for Ewing sarcoma
July 16, 2020
New insights into Ewing sarcoma, an aggressive childhood cancer, were published July 15 in the prestigious journal Nature. Researchers from the Long School of Medicine at The University of Texas Health Science Center at San Antonio contributed to the study. Ewing sarcoma is a bone and soft tissue cancer that primarily affects children and adolescents. […]
The Cancer Letter: Ruben Mesa: Facing a dramatic COVID-19 spike in San Antonio
July 13, 2020
Dr. Ruben Mesa, Mays Cancer Center Director, contributes to The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. Read the story.